Paroxetine treatment of generalized social phobia (social anxiety disorder) - A randomized controlled trial

被引:281
作者
Stein, MB
Liebowitz, MR
Lydiard, RB
Pitts, CD
Bushnell, W
Gergel, I
机构
[1] Univ Calif San Diego, Dept Psychiat 0985, La Jolla, CA 92093 USA
[2] Columbia Univ Coll Phys & Surg, Dept Psychiat, New York, NY 10032 USA
[3] Med Univ S Carolina, Dept Psychiat, Charleston, SC 29425 USA
[4] SmithKline Beecham Pharmaceut, Clin Res Dev & Med Affairs N Amer, Collegeville, PA USA
来源
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION | 1998年 / 280卷 / 08期
关键词
D O I
10.1001/jama.280.8.708
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Context.-The generalized type of social phobia (social anxiety disorder) is a severe and often disabling form of social anxiety that affects approximately 5% of the general population. Earlier research has shown monoamine oxidase inhibitors or benzodiazepines to be effective in treating this condition, but neither has achieved widespread use. Objective.-To compare the efficacy of paroxetine, a selective serotonin reuptake inhibitor, with placebo in adults with generalized social phobia. Design.-Twelve-week, multicenter, randomized, double-blind trial. Setting.-Thirteen centers across the United States and 1 in Canada. Participants.-Between April 13, 1995, and February 28, 1996, 187 persons meeting Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition criteria for generalized social phobia were randomized land 183 returned for at least 1 efficacy assessment) to treatment. Intervention.-After a 1-week, single-blind, placebo, run-in period, patients received a double-blind, 1 I-week course of either paroxetine or matching-image placebo. The initial daily dosage of paroxetine (or placebo) was 20 mg with increases of 10 mg/d weekly (flexible dosing to a maximum of 50 mg/d) permitted after the second week of treatment. Main Outcome Measures.-Number of responders based on the Clinical Global Impression Global Improvement Item ("much improved";or "very much improved"); mean change from baseline on the Liebowitz Social Anxiety Scale total score. Results.-Fifty (55.0%) of 91 persons taking paroxetine and 22 (23.9%) of 92 persons taking placebo were much improved or very much improved at the end of treatment (odds ratio [OR], 3.88; 95% confidence interval [CI], 2.81-5.36). Mean Liebowitz Social Anxiety Scale total scores were reduced by 39.1% (the mean baseline score of 78.0 declined by a mean of 30.5 points at follow-up) in the paroxetine group compared with 17.4% (the mean baseline score of 83.5 declined 14.5 points at follow-up) in the placebo group, a difference of 21.7% (95% CI, 8.7%-34.7%) favoring paroxetine. Conclusions.-Paroxetine is an effective treatment for patients with generalized social phobia. Short-term (ie, 11-week) treatment results in substantial and clinically meaningful reductions in symptoms and disability. Future research should test whether these may be further reduced by extended treatment or supplementation with specific educational-cognitive-behavioral techniques.
引用
收藏
页码:708 / 713
页数:6
相关论文
共 49 条
  • [1] CONTEMPORARY MANAGEMENT OF DEPRESSION
    ANDREWS, JM
    NEMEROFF, CB
    [J]. AMERICAN JOURNAL OF MEDICINE, 1994, 97 : S24 - S32
  • [2] [Anonymous], 1997, Eur Arch Psychiatry Clin Neurosci, V247, P71
  • [3] ANTONY MM, 1997, PSYCHIATRY, P1037
  • [4] BERK M, 1995, J CLIN PSYCHIAT, V56, P36
  • [5] BLACK B, 1992, J CLIN PSYCHOPHARM, V12, P293
  • [6] COHN CK, 1990, J CLIN PSYCHIAT, V51, P28
  • [7] DAVIDSON JRT, 1993, J CLIN PSYCHOPHARM, V13, P423
  • [8] denBoer JA, 1997, BRIT MED J, V315, P796
  • [9] DEWILDE J, 1993, ACTA PSYCHIAT SCAND, V87, P141
  • [10] FIFER SK, 1994, ARCH GEN PSYCHIAT, V51, P740